Corbus Pharmaceuticals Holdings Inc. [NASDAQ: CRBP] traded at a high on 05/25/21, posting a 5.33 gain after which it closed the day’ session at $1.78. The company report on May 25, 2021 that Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021.
Details of the presentations are as follows:.
The results of the trading session contributed to over 2301938 shares changing hands. Over the past one week, the price volatility of Corbus Pharmaceuticals Holdings Inc. stands at 7.27% while the volatility over the past one month is 8.63%.
The market cap for CRBP stock reached $213.80 million, with 125.03 million shares outstanding and 123.76 million shares in the current float. Compared to the average trading volume of 4.25M shares, CRBP reached a trading volume of 2301938 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Corbus Pharmaceuticals Holdings Inc. [CRBP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRBP shares is $2.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRBP stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Corbus Pharmaceuticals Holdings Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 08, 2020. The new note on the price target was released on September 08, 2020, representing the official price target for Corbus Pharmaceuticals Holdings Inc. stock. Previously, the target price had yet another drop from $18 to $2.50, while Jefferies kept a Hold rating on CRBP stock.
The Average True Range (ATR) for Corbus Pharmaceuticals Holdings Inc. is set at 0.14, with the Price to Sales ratio for CRBP stock in the period of the last 12 months amounting to 76.36. The Price to Book ratio for the last quarter was 2.25, with the Price to Cash per share for the same quarter was set at 1.03.
How has CRBP stock performed recently?
Corbus Pharmaceuticals Holdings Inc. [CRBP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.20. With this latest performance, CRBP shares dropped by -4.30% in over the last four-week period, additionally plugging by 47.11% over the last 6 months – not to mention a drop of -77.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRBP stock in for the last two-week period is set at 53.48, with the RSI for the last a single of trading hit 58.17, and the three-weeks RSI is set at 50.71 for Corbus Pharmaceuticals Holdings Inc. [CRBP]. The present Moving Average for the last 50 days of trading for this stock 1.8146, while it was recorded at 1.7120 for the last single week of trading, and 2.3664 for the last 200 days.
Corbus Pharmaceuticals Holdings Inc. [CRBP]: Deeper insight into the fundamentals
Corbus Pharmaceuticals Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.50 and a Current Ratio set at 5.50.
Earnings analysis for Corbus Pharmaceuticals Holdings Inc. [CRBP]
With the latest financial reports released by the company, Corbus Pharmaceuticals Holdings Inc. posted -0.52/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRBP.
Insider trade positions for Corbus Pharmaceuticals Holdings Inc. [CRBP]
There are presently around $79 million, or 39.20% of CRBP stock, in the hands of institutional investors. The top three institutional holders of CRBP stocks are: ETF MANAGERS GROUP, LLC with ownership of 6,020,395, which is approximately -25.708% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 5,673,664 shares of the stock with an approximate value of $10.1 million in CRBP stocks shares; and KNOLL CAPITAL MANAGEMENT, LP, currently with $8.98 million in CRBP stock with ownership of nearly 0% of the company’s market capitalization.
59 institutional holders increased their position in Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] by around 11,056,853 shares. Additionally, 40 investors decreased positions by around 6,268,159 shares, while 28 investors held positions by with 26,780,919 shares. The mentioned changes placed institutional holdings at 44,105,931 shares, according to the latest SEC report filing. CRBP stock had 21 new institutional investments in for a total of 842,449 shares, while 18 institutional investors sold positions of 1,571,956 shares during the same period.